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Background: Nivestim™ (filgrastim) is a follow-on biologic agent licensed in the EU for the treatment of neutro-
penia and febrile neutropenia induced by myelosuppressive chemotherapy. Nivestim™ has been studied in phase 2
and 3 clinical trials where its efficacy and safety was found to be similar to its reference product, Neupogen®.
Follow-on biologics continue to be scrutinised for safety. We present a design for two observational phase IV
studies that are evaluating the safety profile of Nivestim™ for the prevention and treatment of febrile neutropenia
(FN) in patients treated with cytotoxic chemotherapy in general clinical practice.
Methods/Design: The NEXT (Tolérance de Nivestim chez les patiEnts traités par une chimiothérapie anticancéreuse
cytotoXique en praTique courante) and VENICE (VErträglichkeit von NIvestim unter zytotoxischer Chemotherapie in
der Behandlung malinger Erkrankungen) trials are multicentre, prospective, longitudinal, observational studies
evaluating the safety profile of Nivestim™ in ‘real-world’ clinical practice. Inclusion criteria include patients
undergoing cytotoxic chemotherapy for malignancy and receiving Nivestim as primary or secondary prophylaxis
(NEXT and VENICE), or as treatment for ongoing FN (NEXT only). In accordance with European Union
pharmacovigilance guidelines, the primary objective is to evaluate the safety of Nivestim™ by gathering data on
adverse events in all system organ classes. Secondary objectives include obtaining information on patient
characteristics, efficacy of Nivestim™ therapy (including chemotherapy dose intensity), patterns of use of Nivestim™,
and physician knowledge regarding filgrastim prescription and the reasons for choosing Nivestim™. Data will be
gathered at three visits: 1. At the initial inclusion visit, 2. At a 1-month follow-up visit, and 3. At the end of
chemotherapy.
Recruitment for VENICE commenced in July 2011 and in November 2011 for NEXT. VENICE completed recruitment
in July 2013 with 407 patients, and NEXT in September 2013 with 2123 patients. Last patient, last visit for each
study will be December 2013 and March 2014 respectively.
Discussion: The NEXT and VENICE studies will provide long-term safety, efficacy and practice pattern data in
patients receiving Nivestim™ to support myelosuppressive chemotherapy in real world clinical practice. These data
will improve our understanding of the performance of Nivestim™ in patients encountered in the general patient
population.
Trial registration: NEXT NCT01574235, VENICE NCT01627990
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Chemotherapy-induced neutropenia (CIN) is a common
and serious complication of myelosuppressive chemo-
therapy [1]. It is associated with significant morbidity
and mortality [1], and can increase the overall cost of
providing cancer therapy [2,3]. CIN can severely impair
host defence systems, leading to an increased risk of life-
threatening infections [3]. CIN may progress to febrile
neutropenia (FN), which is an important contributor to
chemotherapy-associated morbidity and mortality, and
carries a high risk of death from systemic infection. Pa-
tients who develop FN (body temperature >38.5°C with
absolute neutrophil count <0.5×109/L) are stratified as
high or low risk according to the Multinational Associ-
ation for Supportive Care (MASCC) index. High-risk pa-
tients are generally treated in an in-patient setting with
broad-spectrum intravenous antibiotics. Lower risk pa-
tients are also admitted to hospital, but can be managed
with oral antibacterial agents [4].
FN can result in substantial dose reductions and delays
to chemotherapy cycles that may jeopardise treatment
outcomes, prolonging patient recovery, and diminish the
success of antineoplastic therapy [5-7]. Dose reductions
and delays in chemotherapy have been associated with
worse patient outcomes in many cancers [5], including
colorectal cancer [8], non-small-cell lung cancer [9] and
breast cancer [10]. There is recent evidence that the im-
pact on survival of chemotherapy dose modification may
be lessened with newer therapies, such as platinum and
taxane regimens in ovarian cancer [11] and cisplatin/car-
boplatin with vinorelbine/gemcitabine in NSCLC [12].
For over two decades, granulocyte colony-stimulating
factors (G-CSFs; filgrastims) have been the mainstay of
the treatment and prevention of CIN [13], where they
have been found to reduce the risk of neutropenia across
a range of patient settings, decrease the incidence of FN,
reduce the incidence of infection, reduce the require-
ment for treatment with antibiotics, and accelerate neu-
trophil recovery [6,14-17]. Importantly, use of G-CSFs in
patients undergoing myelosuppressive chemotherapy can
reduce the need for physicians to delay chemotherapy cy-
cles or reduce chemotherapy doses [18,19].
Along with the development of G-CSFs, advances in
cancer care have been accompanied by reduced require-
ments for dose reduction and delay due to FN. A recent
observational study of 1,849 patient records in the
United States indicated that relatively few patients now
receive high-risk regimens, and that treatment of FN to
limit dose reduction and delay is chiefly reactive rather
than prophylactic [20]. The apparent lack of prophylactic
use of G-CSF may be driven in part by continuing de-
bate over its survival benefits. A 2007 systematic review
of 17 randomised controlled trials of G-SCF use in
patients with solid tumours or lymphoma found thatprophylactic G-CSF reduced the risk of FN and early
death, including infection-related mortality [18]. In con-
trast, another meta-analysis conducted in the same year,
this time on 148 trials, found no effect of prophylactic
G-CSF on mortality, but did identify reduced risk of in-
fection [21]. Elderly HER-positive breast cancer patients,
specifically those receiving adjuvant dose-dense chemo-
therapy, also appear to derive no benefit from prophylac-
tic G-CSF [22]. The most recent update of the EORTC
guidelines on the use of G-CSF in chemotherapy pa-
tients acknowledges that data supporting prophylactic
use are mixed, and echo the recommendations of the
American Society of Clinical Oncology (ASCO) that
prophylactic use of G-CSF should be reserved for high-
risk (>20%) patients [6].
The cost of G-CSF use has come under scrutiny from
various quarters, and ASCO has identified five key im-
peratives to improve cancer care at reduced cost, one of
which is to ensure that prophylactic use of G-CSF is re-
served only for patients with a high risk of FN (>20%),
and where treatment regimens not requiring G-CSF are
unavailable [23,24]. The approval of biosimilar versions
of the originator products is increasing physician choice,
improving patient access and has the potential to reduce
costs associated with therapy [25]. Biosimilars are follow-
on versions of peptide therapeutics and are produced by
companies other than the company that marketed the ori-
ginal product. In contrast with small molecule generic
drugs, it is not possible to make a completely identical
copy of a peptide therapeutic, chiefly because, although
the patent on the compound may have expired, the pro-
cess used to make it remains proprietary, and various fac-
tors in the manufacturing and formulation processes can
result in subtle variations between biosimilars and their
reference product [26]. For these reasons, the European
Medicines Agency (EMA) has produced several sets of
stringent guidelines that must be adhered to in the devel-
opment of biosimilar products [27-30]. These state that
biosimilars must demonstrate similarity to the reference
product in terms of molecular characterisation, purity, sta-
bility, pharmacokinetics, pharmacodynamics, clinical effi-
cacy, tolerability and safety.
In the field of filgrastims, six biosimilar compounds
have been approved according to the EMA standards,
including Nivestim™ (Hospira filgrastim) [31]. Through-
out the whole of its development programme, which has
included a large-scale phase III clinical trial, Nivestim™,
has demonstrated similarity in quality, safety and efficacy
to its reference product Neupogen® [32-35]. However,
despite proven similarity to Neupogen® in accordance
with EMA standards, some physicians remain con-
cerned over the safety of biosimilars in a range of in-
dications, and seek reassurance from long-term safety
studies [25,36-39].
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two phase IV, post-marketing, longitudinal, observational,
safety and efficacy studies that will gather additional long-
term data to evaluate the safety profile of Nivestim™ for
the prevention and treatment of FN in clinical practice
given according to available clinical practice guidelines
and the product label [6,40]. These studies are being con-
ducted in France and Germany alongside an existing pan-
European pharmacovigilance programme. In this paper
we will describe the design of both of these studies.
Methods
Objectives
The authors present the design of two phase IV, longi-
tudinal, observational, safety and efficacy studies that
will evaluate the safety profile of biosimilar G-CSF
(Nivestim™) for the prevention and treatment of FN in
patients undergoing cytotoxic chemotherapy. The two
observational studies are termed NEXT (Tolerance de
Nivestim chez les patiEnts traités par une chimiothé-
rapie anti-cancéreuse cytotoXique en praTique cour-
ante; NCT01574235) and VENICE (VErträglichkeit
von NIvestim unter zytotoxischer Chemotherapie in der
Behandlung maligner Erkrankungen; NCT01627990). The
studies aim to evaluate the safety of a biosimilar G-CSF by
producing evaluable long-term data on its use in a large
patient population, without the constraints of a rando-
mised controlled trial. The safety evaluation will include
the recording of adverse events (AEs) in all system organ
classes, as required by European Union (EU) pharmaco-
vigilance guidelines.Table 1 Information included on case report forms for baselin
Baseline visit
• Informed consent
• Criteria for inclusion and exclusion
• General information relating to the patient being
• treated (status, demographic)
• Vital parameters
• Medical and surgical anamnesis (FN, recurrent infections, HIV, COPD, cardiov
diseases, renal or hepatic insufficiency)
• Preceding treatments (chemotherapy, radiotherapy and/or surgery)
• Information relating to pathology of malignant haemopathies (Hodgkin’s, n
TNM, stem-cell transformations)
• Information relating to the pathology of solid tumours (localisation, TNM)
• Laboratory (haemoglobin, thrombocytes, leukocytes, neutrophil, CRP, CD34+
• Infections (type, localisation, additional factors [hypotension, dermatitis, erys
• Description of chemotherapy (aims, schedule, duration, cycles, active princip
• Prescription of Nivestim (primary/secondary prophylaxis, dosage, duration, a
Abbreviations: ANC absolute neutrophil count, HIV human immunodeficiency virus, C
AEs adverse events.In addition to safety parameters, the studies will also
gather information on efficacy outcomes, patients’ char-
acteristics, lab values, indications for treatment, patterns
of use of Nivestim™, evaluation of dose intensity, phy-
sician knowledge regarding G-CSF prescription and the
reasons for choosing Nivestim™ over other available the-
rapies. The VENICE study will also collect data on levels
of CD34+ cells in the blood, as this may have predictive
value as a marker of stem-cell reserves and regenerative
capability [41-43].
Study populations
VENICE is currently being conducted in Germany and
NEXT is being conducted in France – both studies are
being conducted by practicing oncologists and haemato-
logists. VENICE and NEXT began recruitment in July
2011 and November 2011, respectively, and are recruiting
subjects from 70 sites in Germany and 160 sites in France.
Site selection is based on their particular focus on oncol-
ogy and haematology. NEXT aimed to recruit 2,000 adult
patients in total, while VENICE aimed to recruit 700 adult
and paediatric patients (no age limits). Both studies will
recruit over a period of 24 months with a maximum
follow-up period of 6 months for each patient.
The studies will include three patient visits: 1. Inclu-
sion visit. 2. First follow-up visit after the first course of
Nivestim™. 3. Second follow-up visit at the end of the
chemotherapy regimen after the last cycle of chemothe-
rapy. The patient information collected at each visit is
shown in Table 1.
Inclusion and exclusion criteria are shown in Table 2.e and follow-up visits
Follow-up visits
• ANC-nadir, ANC-value
• AEs (hospitalisation, clinically relevant)
• Vital parameters
• Blood tests
• Description of chemotherapy including dose
modifications
ascular • Prescription of Nivestim™
• Withdrawal before end of study, including
reasons and date





OPD chronic obstructive pulmonary disease, CRP C-reactive protein,
Table 2 Inclusion and exclusion criteria for NEXT and
VENICE
Inclusion criteria Exclusion criteria
• Adult patients (NEXT) • Chronic myeloid leukaemia
• Adult and paediatric patients
(VENICE)
• Myelodysplastic syndrome
• Solid tumours or
haematological malignancies
• Hypersensitivity to the active
substance
• Treated or planned treatment
with cytotoxic chemotherapy
irrespective of cycle
• Hypersensitivity to one of the
excipients of Nivestim™
• Indicated for G-CSF therapy
according to the product label
for Nivestim™
• Undergoing treatment with
G-CSF for ongoing FN (curative)
(VENICE only)*
*NEXT includes two patient profiles: curatively and prophylactically treated
patients; VENICE includes only patients treated prophylactically. Patients are
not excluded if they have congenital neutropenia disorders or have received
stem cell transplants.
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In clinical practice, primary prophylaxis of CIN with a
filgrastim is recommended in patients undergoing che-
motherapy where the estimated risk of developing FN
is ≥20%, or for patients undergoing chemotherapy with
FN risk factors and a risk of developing FN of ≥10%.
Secondary prophylaxis with filgrastim is recommended
only for patients in whom a dose reduction would com-
promise therapy success or result in a reduction of over-
all survival, or in patients who have experienced FN with
previous treatment. In line with these recommendations,
the NEXT and VENICE studies, will allow the use of
Nivestim™ for both primary and secondary prophylaxis.
The prophylactic dosage will be s.c. or i.v. Nivestim™
5 μg/kg/day, and the first injection will be administered
between 24 and 72 hours after the cytotoxic chemother-
apy. G-CSF therapy will continue until the expected time
the neutrophil nadir has passed or until the post-nadir
blood neutrophil count returns to a level within the nor-
mal range (above 1,000 cells/mm3).
Curative treatment (treatment for ongoing FN) is also
possible in NEXT and VENICE; however, patients trea-
ted in this manner will be omitted from the documen-
tation and analysis. The curative use of G-CSF will be
limited to patients with FN and patients with signs of
serious infection such as major tissue or fungal infection,
and the dose used will be the same as that for prophylac-
tic therapy. In curative circumstances, and in common
with prophylactic use, G-CSF therapy will continue until
the post-nadir blood neutrophil count is above 1,000
cells/mm3. Studies of filgrastim in patients with severe
impairment of renal or hepatic function have shown it
exhibits similar pharmacokinetic and pharmacodynamic
profiles to those seen in normal individuals; therefore, it
is not necessary to modify the Nivestim™ dose in patients
with renal or hepatic dysfunction [40].Endpoints
NEXT and VENICE are both gathering similar endpoints
on the safety and clinical efficacy of Nivestim. The pri-
mary endpoint is the safety and tolerability of Nivestim™
evaluated by the collection of data on all AEs experi-
enced by patients as well as the incidence of and reasons
for hospitalisation. The secondary endpoints are varied
and include efficacy and practice pattern data. For base-
line patient characteristics, the study will record data on
socio-demographics, surgical and therapeutic medical his-
tories, the nature of the patients’ malignancies (including
location and stage), details of previous chemotherapy
received, and clinical and laboratory parameters before
treatment with Nivestim commenced. In the VENICE
study only, data will be recorded on the CD34+ count at
baseline. In the analysis, the CD34+ count will also be
used to stratify patients according to high (i.e. good
haematopoeitic reserve) and low (poor haematopoetic
reserve) values at Visit 1. In studies of patients with
Hodgkin’s and non-Hodgkin’s lymphoma, CD34+ levels
can predict the progenitor cell yields [41,42].
For the efficacy endpoints, both studies will assess the
clinical effectiveness of Nivestim™ according to the du-
ration of neutropenia (number of days with grade 4 neu-
tropenia with an ANC <0.5×109/L), the incidence and
duration of FN (body temperature of >38.5°C for more
than 1 hour and ANC <0.5×109/L on the same day), the
occurrence of infection, delay of chemotherapy cycles,
chemotherapy dose reductions due to neutropenia, and
circulating ANC levels on the final day of filgrastim
therapy.
Using a questionnaire, the studies will also collect data
concerning the mode of treatment of patients with
Nivestim™, including indication for treatment, dose,
route of administration, treatment duration, and any
delay in the initiation of Nivestim™ treatment owing to
chemotherapy treatment. Timings of ANC nadir and
chemotherapy adjustments will also be recorded.
To understand the factors that influence prescribing
behaviour for biosimilar filgrastims, both studies will
collect data on physician age, sex, specialty, practice
structure and job title. Additionally, their general and
specific G-CSF prescribing habits will be observed.
Statistical analysis
NEXT and VENICE will analyse the outcomes for all
subjects and all researched study populations – all data
will be described in the analyses and missing data will
not be substituted. The analysis sets for the studies will
comprise an all-treated set, a safety set, an efficacy set
and an investigator set.
The all-treated set will be made up of patients who
have received Nivestim™ at least once, and whose enrol-
ment visit was documented. The safety set will include
Table 3 Evaluation of AEs in NEXT and VENICE
All AEs will be evaluated according to:
• Clinical relevance
• Degree of seriousness (if deemed serious, a description of the
outcome of each AE, e.g. death, life-threatening, hospitalisation, will be
given)
• Intensity (mild, moderate, severe)
• Outcome (restoration, persistent damage, etc.)
• Relationship to G-CSF therapy (none, possible, probable)
• Occurrence of AEs relative to the first administration of Nivestim
treatment
• Any measures taken with regard to Nivestim™ therapy (none,
reduction of dose, discontinuation, temporary suspension).
Kamioner et al. BMC Cancer 2013, 13:547 Page 5 of 9
http://www.biomedcentral.com/1471-2407/13/547patients from the all-treated set for whom at least one
further visit has been documented. A sub population
analysis of the safety set will involve stratification by age
(<18, 18–65, >65 years), and stratification by tumour
type (haematological versus solid).
The efficacy set will include patients from the safety
analysis set who fulfil all the inclusion and exclusion cri-
teria and whose baseline ANC value and one other ANC
value (ANC-nadir/ANC-value) has been documented
either during the therapy or shortly afterwards. In
VENICE, patients from the efficacy analysis set will
be stratified according to baseline CD34+ cell counts
(low or high).
The investigator set will include all participating
physicians who have at least partially completed the
Physician’s Questionnaire.
Endpoints with quantitative variables will be described
in terms of the number of values, the number of missing
values, means, medians, standard deviation, minima and
maxima. Endpoints with qualitative data will be repre-
sented with percentages and frequencies. The duration
of each patient’s participation in the studies will be fac-
tored such that incidence rates can be extrapolated to
patient-years.
The level of significance for the two observatio-
nal studies has been set at 0.05; however, NEXT and
VENICE have used different methods for estimating the
required sample size to accurately represent the pro-
portion of patients who will be hospitalised because of
FN or infection during the study. For the NEXT study,
the sample size was based on the results of a 2003 on-
cology survey conducted by Louis Harris & Associates
of 285,000 cancer patients treated with cytotoxic chemo-
therapy. Of these patients, 68,000 received G-CSF treat-
ment. Using this figure of 68,000 patients, enrolment of
2,000 patients is required for NEXT to identify events in
the overall population that are predicted to occur at an
incidence of 1 ± 2.16%. For VENICE, the investigators
calculated the required sample size by using an estima-
tion of the proportion of patients who will be hospita-
lised due to FN or an infection during the observational
phase of the study. In this case, assuming a maximum
probability for the occurrence of hospitalisation due to
FN or infection is 20% for each patient recruited, a
sample size of n = 683 patients is needed to attain a 95%
confidence interval (CI) with an accuracy level of ±3%.
Taking into account a potential drop-out rate of 2.5%, 700
patients are required for VENICE.
For the safety analysis, the average time of occurrence
of each type of AE will be calculated, and results will be
described using descriptive statistics. Additionally, the
characteristics of patients with each type of AE will be
described in detail. The categorisation for the evaluation
of AEs is given in Table 3.During both studies, the number of patients requiring
hospitalisation will be recorded together with the rea-
sons for hospitalisation. The incidence of hospitalisation
due to FN or infection will be represented as absolute
and relative frequencies (%, patient-years). Potential risk
factors for the occurrence of hospitalisation will be iden-
tified and quantified using a multivariate survival ana-
lysis (Cox regression). Cases of hospitalisation will be
described in detail, including the reason (FN or infection
[bacterial, fungal or viral]), the duration of FN or infec-
tion, and the start time of FN or infection relative to the
administration of Nivestim™.
All statistical analyses will be performed using SAS
version 9.13 or later.
Study limitations
Clinical trial populations are a narrow representation of
the population of patients encountered in routine clini-
cal practice. Both the NEXT and VENICE studies present
an opportunity to record and analyse the performance of
a biosimilar filgrastim over an extended period in a diverse
group of patients. However, the study designs have some
inherent limitations. For NEXT, the diversity of the patient
characteristics may create statistical noise in the analyses,
but this may be lessened by the large sample size. Add-
itionally, due to the observational nature of the NEXT
study there is no control arm to enable comparison of the
performance of different filgrastims in the treatment of
CIN. VENICE shares the general limitations of NEXT, but
also has a relatively low sample size, and includes a
mixture of adults and paediatric patients that may
confound analyses.
Discussion
Recruitment began in July 2011 for the VENICE study
and in November 2011 for the NEXT study. As of Sep-
tember 2013, both studies have completed recruitment.
VENICE has 407 patients enrolled and NEXT has 2123
patients (Figure 1). Currently, both studies are still on
Figure 1 Enrolment into NEXT and VENICE as of 31 September 2013.
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pleted in December 2013 and NEXT will be completed
in March 2014.
The NEXT and VENICE studies will provide additional
information on the long-term safety and efficacy of
Nivestim™ in patients being treated for malignancy with
cytotoxic chemotherapy. The growing prominence of
biosimilars among the therapeutic armamentarium and
the improved access that they offer means that confi-
dence in their safety is paramount.
In accordance with the standards set by the EMA
[27-30], studies on Nivestim™ have demonstrated that
it is equally as effective as the reference product,
Neupogen®, and has a similar safety profile [33-35]. A
phase III randomised equivalence trial in 279 breast
cancer patients found that the mean duration of se-
vere neutropenia (DSN) was 1.3 days for Neupogen®
and 1.6 days for Nivestim™, which met the protocol-
defined criteria for bioequivalence [35]. Secondary
endpoints also showed Nivestim™ to be equivalent to
Neupogen® in terms of time to absolute neutrophil count
(ANC) recovery and incidence of FN [35]. These data sup-
ported the findings of two phase I trials studying the
pharmacokinetics and pharmacodynamics of Nivestim™.
In these studies, the efficacy, safety and pharmacokinetic
characteristics of Nivestim™ and Neupogen® were found to
be equivalent in healthy volunteers [33,34]. The studies
performed with Nivestim™ were sufficient to satisfy the
EMA that the quality of the drug and its performance ver-
sus the reference compound Neupogen® was sufficient to
warrant approval for the treatment and prevention of neu-
tropenia in patients undergoing myelosuppressive che-
motherapy and those with severe idiopathic neutropenia,those with neutropenia arising from primary HIV infec-
tion and for the mobilisation of peripheral blood stem
cells [40].
As more biosimilar filgrastims have become available,
the pharmaceutical industry and the clinical community
have continued to watch with interest how this relatively
new class of agents performs in patients and whether
any differences in the agents may become apparent as
time passes and increasing numbers of patients are
treated. The biosimilar manufacturers have continued to
support investigation of their products even after they
have been approved, and differences in performance be-
tween biosimilar drugs and the reference product have
been found to favour biosimilars. For instance, studies of
the biosimilar filgrastim XM02 have found the level of
impurities evident in the XM02 product to be less than
those found in Neupogen® [36]. Additionally, the thermal
stability of Nivestim™ has been shown to be sufficient to
enable out-of-fridge storage for up to 7 days without ap-
pearance of impurities or additional degradation pro-
ducts – a property not shared with other filgrastims [44].
NEXT and VENICE come at a time regulators are
seeking data from long-term observational studies in
clinical practice. In many cases, regulatory agencies will
approve a drug for clinical use and ask that additional
data be gathered via pharmacovigilance programmes or
via specifically designed phase IV clinical trials. In the
UK, the Medicines and Healthcare products Regulatory
Agency MHRA has been examining its approval process
for medicines, and has gone as far as to suggest that cer-
tain new agents should receive an accelerated provisional
approval based on registrational clinical trials, and that
drugs should then be subject to close monitoring in a ‘real
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has contributed to the UK Clinical Research Collaboration
report and the National Institute for Health Research’s
Research Capability programme, which together have
demonstrated the possibility for collecting long-term data
on a large scale [46,47]. The MHRA has concluded that
population-based data will have a beneficial effect on ob-
servational and interventional research, and the agency
has also suggested that it is prepared to assist in the deve-
lopment of surveillance methodologies to achieve this
[48]. It is therefore important to ensure that physicians
and regulatory agencies have access to comprehensive
data that accurately reflects the performance of biosimilar
filgrastims in the clinic.
Conclusion
Owing to the duration of the studies, the large number
of patients planned for enrolment in multiple centres,
and the clinical practice setting of NEXT and VENICE,
these studies will produce a significant amount of com-
prehensive, high-quality, evaluable data relating to the
safety, efficacy and clinical use of Nivestim™. The large
cohort of patients, particularly for NEXT, will enable the
objective evaluation of the safety and efficacy profiles of
Nivestim™.
Access to filgrastims remains limited for many patients
and physicians in the EU [25]. The NEXT and VENICE
studies will provide healthcare agencies with much
needed additional data, and may assist in maintaining
and expanding access to biosimilar filgrastims for the
treatment of CIN.
Observational studies of differing designs have been
conducted in chemotherapy-induced FN in the past. A
2009 retrospective survey of patient cases in the United
States examined the prevalence of FN and the practices
associated with the delivery of filgrastim and pegfilgrastim.
Pegfilgrastim was associated with a lower incidence of FN
than filgrastim, which was not evident in the clinical trials
for pegfilgrastim [49]. This finding underscores the need
for observational studies to reveal differences that do not
emerge in clinical trials, and highlights that variations in
real world clinical practice can have an impact on the
overall effectiveness of therapeutic interventions.
The value of observational studies has been further
highlighted by an observational study that examined
G-CSF use in chemotherapy principally from the point
of view of cost [20]. This study of 1,849 lung and colo-
rectal cancer patients found that 17% and 18% of pa-
tients on high-risk and intermediate-risk chemotherapy
regimens received G-CSF, in contrast to 10% on low-risk
regimens. Patients enrolled in a health maintenance or-
ganisation (HMO) were less likely to receive G-CSFs
compared with non-HMO patients [20]. Neither of these
findings are particularly surprising; however, the studyalso found that 96% of patients were receiving G-CSF
in clinical situations outside of label- and guidelines-
mandated indications [20]. This is a major deviation
from recommended practice, the type of which could
only be revealed in an observational study. These kinds of
data support the notion of ASCO that there are opportu-
nities to improve care and reduce the cost of G-CSF the-
rapy [23]. NEXT and VENICE are designed differently,
and use label-mandated posology for the administration of
G-CSF. In this way, the NEXT and VENICE trials will an-
swer different clinical questions to existing observational
studies, and thereby add to the totality of real world data
on supportive care for cancer.
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